New Arrivals/Restock

INTERNAL MEDICINE 2026 VOLUME 2: Pathophysiology to Bedside Practice with Current Clinical Guidelines for USMLE and ABIM Board Preparation

flash sale iconLimited Time Sale
Until the end
04
57
07
Free shipping for purchases over $99 ( Details )
Free cash-on-delivery fees for purchases over $99
Please note that the sales price and tax displayed may differ between online and in-store. Also, the product may be out of stock in-store.
New  $90.00
quantity

Product details

Management number 233565860 Release Date 2026/06/27 List Price $90.00 Model Number 233565860
Category

It is 3 AM. Your septic shock patient is not responding to crystalloid. The attendings disagree about adding vasopressin now or waiting on hydrocortisone. You reach for your review book. It tells you what to use. It does not tell you why, when, or which landmark trial settled the question. You close it knowing what you already knew.This second volume of Internal Medicine 2026 was built to close that gap.Ten chapters move systematically through hematology and oncology, infectious disease, rheumatology, neurology, preventive medicine, geriatrics, and critical care. Every condition is traced from cellular mechanism to prescribing decision, and every recommendation is anchored to the trial that produced it. ProCESS. APROCCHSS. DAPA-HF. CLARITY-AD. CARAVAGGIO. PROSEVA. TRICC. MINT. These studies are not footnotes here. They sit inside the discussion of the patient you will treat tomorrow.Each chapter delivers diagnostic frameworks that organize complex differentials, dosing and monitoring details that separate competence from excellence, mid-chapter checkpoints for active recall, extended case discussions with focused questions and pearls, and an answer key written as a teaching essay rather than a one-line response. A full-length 150-question assessment mirrors the structure and reasoning depth of the licensing tests residents actually face.The content reflects evidence through early 2026: lecanemab and donanemab for early Alzheimer disease, exa-cel CRISPR therapy for sickle cell, resmetirom for MASH, terlipressin for hepatorenal syndrome, the BPaL regimen for resistant tuberculosis, four-pillar HFrEF therapy, and GLP-1 cardiovascular outcomes integrated into daily decision-making.Residents, fellows, senior medical students, and physicians preparing for certification or recertification will recognize this as the resource they have been searching for.Open the first chapter and begin where your next rotation needs you to begin. Read more

ASIN B0H2MK2FVP
XRay Not Enabled
Format Print Replica
Edition 2nd
Language English
File size 16.5 MB
Page Flip Not Enabled
Word Wise Not Enabled
Book 2 of 2 INTERNAL MEDICINE 2026
Print length 596 pages
Accessibility Learn more
Publication date May 22, 2026
Enhanced typesetting Not Enabled

Correction of product information

If you notice any omissions or errors in the product information on this page, please use the correction request form below.

Correction Request Form

Product Review

You must be logged in to post a review